C4A and type 2 diabetes mellitus: In conclusion, daily oral volixibat – a highly potent and selective ASBT inhibitor – was minimally absorbed and generally well tolerated, and increased serum C4 levels and faecal excretion of BAs in HVs and patients with T2DM.